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Abstract
Purpose To assess the effect of transcutaneous electrical
nerve stimulation (TENS) for treating refractory overactive
bladder syndrome (OAB).
Patients and methods A consecutive series of 42 patients
treated with TENS for refractory OAB was prospectively
investigated at an academic tertiary referral centre. Effects
were evaluated using bladder diary for at least 48 h and
satisfaction assessment at baseline, after 12 weeks of
TENS treatment, and at the last known follow-up. Adverse
events related to TENS were also assessed.
Results Mean age of the 42 patients (25 women, 17 men)
was 48 years (range, 18–76). TENS was successful fol-
lowing 12 weeks of treatment in 21 (50 %) patients, and
the positive effect was sustained during a mean follow-up
of 21 months (range, 6–83 months) in 18 patients. Fol-
lowing 12 weeks of TENS treatment, mean number of
voids per 24 h decreased significantly from 15 to 11
(p \ 0.001) and mean voided volume increased signifi-
cantly from 160 to 230 mL (p \ 0.001). In addition, TENS
completely restored continence in 7 (39 %) of the 18
incontinent patients. Before TENS, all 42 patients were
dissatisfied or very dissatisfied; following 12 weeks of
TENS treatment, 21 (50 %) patients felt satisfied or very
satisfied (p \ 0.001). No adverse events related to TENS
were noted.
Conclusions TENS seems to be an effective and safe
treatment for refractory OAB warranting randomized,
placebo-controlled trials.
Keywords Transcutaneous electrical nerve stimulation 
Non-neurogenic overactive bladder syndrome
Introduction
Overactive bladder syndrome (OAB), also known as
urgency syndrome or urgency-frequency syndrome, is
characterized by urgency, with or without urgency incon-
tinence, usually with frequency and nocturia, and there is
no proven infection or obvious pathology [1]. OAB is
highly prevalent and affects the lives of millions of people
worldwide, i.e. approximately 15 % of women and 10 % of
men, increasing with advancing age [2]. OAB has a major
impact on quality of life and sexuality [2], and besides the
debilitating manifestations for patients, OAB also imposes
substantial economic burden on every healthcare system, as
direct annual costs are comparable to those of other chronic
diseases such as dementia and diabetes mellitus [3].
Although antimuscarinics are the pharmacological
treatment of choice for OAB, the effectiveness is limited. In
a recent systematic review and meta-analysis of randomized
controlled trials [4], antimuscarinics led to a mean decrease
in incontinence episodes of less than one episode per 24 h
compared to placebo. In addition, many patients discon-
tinue antimuscarinic treatment due to adverse events [5].
Thus, there is an urgent need for effective, well-tolerated
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therapeutic alternatives. Transcutaneous electrical nerve
stimulation (TENS) is an established treatment for OAB in
children [6, 7] and may also be a valuable option in adults.
We therefore investigated, in a prospective study, the effect
of TENS for treating adult patients with refractory OAB.
Patients and methods
Patients
A consecutive series of 42 patients who underwent TENS
for refractory non-neurogenic OAB was prospectively
evaluated. All patients had a complete urological evalua-
tion before considering study enrolment including medical
history, satisfaction assessment, physical examination,
bladder diary for at least 48 h, urinalysis, urine culture,
urethrocystoscopy, bladder washing cytology, and urody-
namic investigation. Study inclusion criteria were non-
neurogenic OAB with urodynamically proven detrusor
overactivity, failed behavioural treatment and pharmaco-
therapy with at least 2 antimuscarinics, each for a mini-
mum of 1 month and titrated to the maximum dose, no
previous surgery for OAB, and no urodynamic signs of
bladder outlet obstruction.
The study was performed in accordance with the ethical
standards expressed in the Declaration of Helsinki. Before
study inclusion, all patients were thoroughly informed, and
informed consent was obtained. Urodynamic studies were
performed according to Good Urodynamic Practices [8].
All methods, definitions and units conform to the stan-
dards recommended by the International Continence
Society [1].
TENS treatment and follow-up assessment
Transcutaneous electrical nerve stimulation was performed
at home with an Alpha 4 Conti (Danmeter A/S, 5000
Odense C, Danmark) stimulation device applying Peri-
form ? vaginal electrodes (Mobilis Healthcare Group,
Lancashire, UK) in women and PEN2 penile electrodes
(Sugar International, Chevillon-sur-Huillard, France) in
men (Fig. 1). Bipolar stimulation with 8 Hz and 400 ls at
sensory threshold level was used for 20 min twice a day.
Effects of TENS treatment were evaluated by bladder
diary for at least 48 h and by satisfaction assessment (i.e.
very satisfied, satisfied/undecided/dissatisfied, very dissat-
isfied). In analogy to the sacral neuromodulation (SNM)
literature [9, 10], success of TENS was defined as an
improvement of more than 50 % in bladder diary variables
(i.e. number of voids, voided volume, and number of
leakages: at least 2 of these 3 variables had to have
improved for considering a treatment success). After
12 weeks of treatment, TENS was discontinued in all
patients and restarted (20 min twice a day) on patient’s
request in the case that OAB symptoms recurred.
Fig. 1 Transcutaneous
electrical nerve stimulation
(TENS) device with vaginal and
circular penile electrodes for
treating refractory overactive
bladder syndrome (OAB)
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Outcome measures
Primary outcome measures were changes in the bladder
diary and in the satisfaction assessment at baseline and
after 12 weeks of treatment.
Secondary outcome measures were changes in the
bladder diary and in the satisfaction assessment in patients
with successful TENS at the last known follow-up.
Tertiary outcome measures were adverse events during
TENS.
Statistical analysis
Data distribution was tested by Q–Q plots. Data were
approximately normally distributed and are shown as the
mean ± standard deviation (SD). For a calculated sample
size of 41 patients, the study was designed to have 80 %
power (b = 0.2) for the paired t-test to detect a difference of
2 voiding episodes and a difference of 50 mL in voided
volume (these differences were estimated to be clinically
relevant) before TENS versus during TENS at a 2-sided
significance level of 2.5 % (a = 0.025), assuming a standard
deviation (SD) of about two times the detectable difference.
The paired t-test and the McNemar’s test were used to
compare related samples, respectively. Comparing unrelated
samples, the unpaired t-test was applied. Statistical analyses
were performed using IBM SPSS Statistics version 19.
Results
Baseline characteristics of the 42 patients (25 women, 17
men) treated with TENS for refractory non-neurogenic
OAB are shown in Table 1.
Transcutaneous electrical nerve stimulation was suc-
cessful following 12 weeks of treatment in 21 (50 %) of
the 42 patients. The positive TENS effect was sustained
during a mean follow-up of 21 months (SD ± 22; range,
6–83 months) in 18 (86 %) of the 21 patients. At the last
known follow-up, 4 of the successfully treated patients
were still under TENS; the 14 remaining had a sustained
effect without treatment.
Following 12 weeks of TENS treatment, mean number of
voids per 24 h decreased significantly (p \ 0.001) from 15
(SD ± 3.6; range, 9–26) to 11 (SD ± 4.8; range, 5–26) and
mean voided volume increased significantly (p \ 0.001)
from 160 mL (SD ± 50; range, 90–300) to 230 mL
(SD ± 85; range, 90–370). In addition, 18 (43 %) of the 42
patients were incontinent before TENS. Following 12 weeks
of TENS treatment, continence was completely restored in 7
(39 %) of the 18 incontinent patients, and the mean number
of pads used per 24 h decreased significantly (p = 0.001)
from 3 (SD ± 1.4; range, 1–6) to 1 (SD ± 1.7; range, 0–7).
Patients’ satisfaction with the lower urinary tract func-
tion changed significantly, following TENS treatment
(p \ 0.001). Before TENS, all 42 patients were dissatisfied
or very dissatisfied. Following 12 weeks of TENS treat-
ment, 21 (50 %) patients felt satisfied or very satisfied.
In a subgroup analysis assessing potential gender
impact, no significant differences (p [ 0.1) between female
and male patients were found.
No adverse events related to TENS occurred during the
study period.
Discussion
Main findings
In patients with refractory non-neurogenic OAB, TENS was
successful following a 12-week treatment period in 50 % of
the patients, and of these, the positive effect was sustained
in more than 80 %. Importantly, no adverse events related
to TENS occurred during the study period. Thus, our find-
ings indicate that TENS may be effective and safe for
treating patients with refractory OAB. However, random-
ized controlled trials are lacking and are highly warranted.
Table 1 Patient baseline characteristics
Characteristics
Total number of patients 42 (100 %)
Women 25 (60 %)
Men 17 (40 %)
Mean age in years 48 (SD ± 16;
range, 18–76)
Mean duration of OAB
symptoms in years
3.2 (SD ± 1.6;
range, 0.75–7.17)
Number of antimuscarinics used
2 16 (38 %)
3 14 (33 %)
4 12 (29 %)
Reasons for quitting
antimuscarinic therapy
Insufficient effect 39 (93%)
Intolerable side effects 3 (7%)
Bladder diary variables
Mean number of voids per 24 h 15 (SD ± 3.6;
range, 9–26)
Mean voided volume 160 (SD ± 50;
range, 90–300)
Number of incontinent patients 18 (43 %)
Number of pads used per 24 h
(incontinent patients only)
3 (SD ± 1.4;
range, 1–6)
SD standard deviation
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Findings in the context of existing evidence
Neuromodulation, both non-invasive and invasive, has
become a well-established and widely accepted treatment in
recent years for patients with OAB. Although the exact
mechanism of action remains to be elucidated, it seems to
involve modulation of spinal cord reflexes and brain net-
works by peripheral afferents [11]. Dorsal clitoral nerve
stimulation during bladder filling reduced the activation of
certain cortical areas suggesting a neuromodulatory effect on
supraspinal centres involved in lower urinary tract control
[12]. In addition, plastic reorganization of cortical networks
triggered by peripheral neuromodulation has been hypothe-
sized [13]. In a PET study of patients treated by SNM for
urgency incontinence [14], the authors proposed that acute
neuromodulation predominantly involves areas associated
with sensorimotor learning, which might become progres-
sively less active during the course of chronic neuromodu-
lation. Moreover, the sympathetic nervous system might
play a role as indicated by studies of low-frequency pudendal
nerve stimulation in cats with chronic spinal cord injury [15].
Percutaneous tibial nerve stimulation (PTNS) has been
shown to be an effective treatment for non-neurogenic
OAB in randomized, double-blind, placebo-controlled trials
[16, 17]. In patients with refractory OAB, SNM was found to
have clear benefits for carefully selected patients, but many
adverse events were reported and redo surgery was often
necessary [18–20]. Pudendal neuromodulation has emerged
as an alternative to SNM, considering a randomized cross-
over study reporting that stimulation of the pudendal nerve
may be more effective than SNM for modulating bladder
activity [21]. Since the pudendal nerves innervate many areas
in the pelvic region including vagina, penis, anal and urethral
sphincters, and the perineal skin, it is possible to stimulate
these pudendal nerve branches non-invasively [22]. Previous
animal studies have shown that vaginal [23] and penile
stimulation [24] can inhibit bladder activity and prevent
incontinence what is in line with the findings of the present
study in humans. Thus, regarding the non-invasiveness, easy
application, and excellent safety profile, TENS may become
a valuable treatment option for refractory OAB before more
invasive methods such as PTNS, intradetrusor botulinum-A-
toxin injections or SNM are considered.
Implications for research
Considering the promising findings of the present study,
further investigations are warranted. Randomized controlled
trials are necessary to demonstrate the efficacy of TENS in
treating OAB. In such prospective trials, both non-neurogenic
and neurogenic OAB, validated disease- and condition-
specific quality of life data, short-, medium- and long-term
results as well as cost-effectiveness issues should be assessed,
and outcomes should be reported with the Consolidated
Standards of Reporting Trials statement [25]. Moreover, it
would be interesting to directly compare TENS and PTNS. At
a glance, PTNS seems to be more effective than TENS,
considering the reported PTNS success rates of 55–71 %
[16, 17]. However, taking into account the different inclusion
criteria, the results are not comparable. The feasibility of
TENS, which can be easily used at home by the patient,
represents a real advantage compared to PTNS, which
requires the insertion of a needle close to the tibial nerve.
Furthermore, the genital nerves are in more proximity to the
sacral plexus than the tibial nerve, and this may, at least from
a theoretical viewpoint, have an effect on treatment efficacy.
In addition, stimulation parameters need further investiga-
tion. Although the TENS device that applied in the present
study allows a wide range of different stimulation settings, we
preset the parameters and did them not adjust to each patient
for homogeneity reasons. However, individual adjustment of
the stimulation parameters in analogy to SNM may improve
the response rate and warrants additional studies. There is
also unclear whether a maintenance-therapy is needed or not.
Indeed, treatment standardization is lacking, and there are no
guidelines for therapeutic and maintenance regimens.
Implications for practice
Overactive bladder syndrome is a widespread chronic ill-
ness that has a major impact on quality of life, affecting
emotional, social, sexual, occupational, and physical
aspects of daily life [26]. Besides the debilitating manifes-
tations for patients, it also imposes substantial economic
burden for every healthcare system [3]. First-line treatment
for OAB includes antimuscarinics, but the treatment
effect is often unsatisfactory, so that other options have to
be considered, including the yet unlicensed intradetrusor
botulinum-A-toxin injections, SNM, or even more invasive
procedures such as bladder augmentation or urinary diver-
sion. Thus, easy, non-invasive, widely available, effective,
and well-tolerated therapeutic alternatives are highly
desirable. Considering the findings of the present study,
TENS may become such a treatment option, especially
taking into account that we only included patients with
refractory OAB, i.e. all our patients had undergone multiple
failed previous treatments (negative patient selection). In
the case that our findings are confirmed in randomized tri-
als, this would have major implications for daily practice
since TENS would have to be propagated widely and
implemented quickly as a standard OAB treatment.
Limitations
The present study has several limitations. First, the results
are based on a non-randomized study without a control
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group. Thus, we are not able to differentiate between the
real TENS effect and the placebo effect. From a patient’s
viewpoint, however, it is most important that a treatment
helps, independent of a potential placebo effect. Second,
we did not assess patients’ quality of life using a validated
OAB-specific questionnaire. Third, including only patients
with refractory non-neurogenic OAB may induce a nega-
tive selection bias. Indeed, the TENS effect may be
underestimated in the present study and is probably more
pronounced in patients with treatment-naive OAB. More-
over, it is unclear whether our results in non-neurological
patients could be extrapolated to patients with neurogenic
OAB, although promising results of transcutaneous pos-
terior tibial nerve stimulation for treating OAB in multiple
sclerosis patients have been found [27]. Fourth, the dura-
tion of the bladder diary may have influenced our results,
i.e. a bladder diary of more than at least 2 days may result
in more reliable data regarding patients’ symptoms. How-
ever, it should be considered that patient compliance
decreases with longer diary duration and that, despite
recent attempts [28], there is no validated generally
accepted bladder diary currently available [29].
Despite the addressed limitations, the present study was
prospective with predefined outcome criteria, and it was
adequately powered and sized to detect differences before
versus during TENS treatment. In addition, the 42 evalu-
ated patients with refractory non-neurogenic OAB with a
mean follow-up of 21 months in the case of successful
TENS treatment seem not insignificant, considering the
lack of data published to date and taking into account the
debilitating manifestations of OAB.
Conclusions
In patients with refractory non-neurogenic OAB, TENS
was successful following a 12-week treatment period in
50 % of the patients, and of these, the positive effect was
sustained in more than 80 % during a mean follow-up of
21 months. Importantly, no adverse events related to TENS
occurred during the study period. Thus, TENS seems to be
an effective and safe treatment for refractory OAB
warranting randomized, placebo-controlled trials.
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